PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Cash & equivalents declining -5.12% while AGEN's grows 13.80%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Below half of AGEN's 17.36%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Other current assets growth < half of AGEN's -53.08%. David Dodd sees a leaner approach to short-term items.
-4.22%
Below half of AGEN's 7.64%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.65%
Below half AGEN's 11.72%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AGEN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AGEN's -32.80%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-47.54%
Below half of AGEN's 3.67%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Below half of AGEN's 6.47%. Michael Burry sees a potential red flag for stagnation or capital shortage.
46.70%
Above 1.5x AGEN's 21.37%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-26.38%
Less than half of AGEN's 34.32%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Below half of AGEN's -36.87%. Michael Burry suspects a big gap in pre-sales traction.
265.71%
Exceeding 1.5x AGEN's 0.66%. Michael Burry suspects ballooning short-term obligations vs. competitor.
63.25%
Above 1.5x AGEN's 4.54%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Less than half of AGEN's 3.63%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x AGEN's 3.97%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.5-0.75x AGEN's -4.60%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
Below half AGEN's -17.71%. Michael Burry sees potential underperformance in building shareholder capital.
-4.84%
Below half AGEN's 6.47%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Below half AGEN's 199.90%. Michael Burry suspects major underinvestment or forced divestment.
-26.37%
Less than half of AGEN's 6.76%. David Dodd sees less overall debt expansion vs. competitor.
5.01%
Less than half of AGEN's -15.70%. David Dodd sees better deleveraging or stronger cash buildup than competitor.